Canopy Growth Corporation — Form 10-K Summary
Period clarification: The supplied filing is the annual report for the fiscal year ended March 31, 2021, not a standalone 2020 fourth-quarter filing. Unless otherwise stated, amounts are in Canadian dollars; financial figures are in millions. The company reports under U.S. GAAP.
Business context and reporting period
Canopy Growth produces and sells recreational and medical cannabis, hemp-derived CBD products, and other consumer products, including Storz & Bickel vaporizers, This Works products and BioSteel sports nutrition. Its principal markets include Canada, the United States (hemp-derived products) and Germany. In the fourth quarter, it changed its reportable segments to global cannabis and other consumer products after the RIV Capital arrangement and restructuring.
Key financial metrics
| Metric | FY ended March 31, 2021 | FY ended March 31, 2020 |
|---|---|---|
| Net revenue | $546.6 | $398.8 |
| Gross margin | $67.0; 12% of revenue | $(31.7); (8%) of revenue |
| Net loss | $(1,670.8) | $(1,387.4) |
| Net loss attributable to Canopy Growth | $(1,744.9) | $(1,321.3) |
| Basic and diluted loss per share | $(4.69) | $(3.80) |
| Adjusted EBITDA loss (non-GAAP) | $(340.3) | $(442.8) |
| Cash used in operating activities | $(465.7) | $(772.6) |
| Free cash flow (non-GAAP) | $(630.2) | $(1,477.6) |
Global cannabis revenue was $378.7 million, up 28%; other consumer products revenue was $168.0 million, up 62%. The global cannabis segment generated a 2% gross margin, versus (26%) in the prior year; other consumer products generated a 36% margin, versus 43%.
At March 31, 2021, cash and cash equivalents were $1,154.7 million and short-term investments were $1,144.6 million. Debt carrying value was $1,583.0 million, including a new US$750 million senior secured term loan facility. Total assets were $6,823.5 million and total shareholders’ equity was $3,486.5 million.
Material changes versus the prior comparable period
- Revenue grew 37%, supported by Canadian recreational sales, new Cannabis 2.0 products, U.S. CBD products, and higher sales from Storz & Bickel and BioSteel.
- Gross margin improved substantially, in part because prior-year restructuring and inventory charges were much larger. FY2021 still faced start-up and underutilization costs, lower production output and an unfavorable mix toward value-priced dried flower.
- Adjusted EBITDA loss narrowed, primarily reflecting lower selling, general and administrative costs. The GAAP net loss increased, driven by volatile non-cash fair-value changes, lower tax recovery and credit-loss charges.
- Operating cash use and free cash flow outflow declined, while investing cash outflow rose to $884.1 million. Financing generated $1,264.8 million, including net Credit Facility proceeds of $877.1 million, CBI warrant exercise proceeds of $245.2 million and stock-option exercise proceeds of $156.9 million.
- Restructuring continued: the company closed or ceased operations at several Canadian and international sites, eliminated approximately 220 positions, and recorded $570.7 million of restructuring, impairment and related costs. It sold two British Columbia facilities for combined proceeds of $40.7 million.
Outlook, management commentary, risks and unusual items
- Management said it had realigned Canadian production to market demand and was focused on improving margins and achieving profitability in the medium term. The filing provides no specific revenue, earnings or cash-flow guidance.
- Management considered liquidity adequate for operations, investment and obligations, citing cash and short-term investments and financing availability. The new facility matures March 18, 2026, bears interest at LIBOR plus 8.50% with a 1.00% floor, is secured by substantially all assets of the borrowers and guarantors, and requires at least US$200 million of quarterly liquidity.
- COVID-19 did not materially affect FY2021 results, according to management, but its future effects remained uncertain and could continue into FY2022. Retail restrictions, discretionary spending and supply-chain disruption were cited as risks.
- Important industry risks include extensive licensing and regulatory requirements; U.S. federal cannabis prohibition and uncertainty around hemp-derived CBD rules; competition, oversupply and price compression; product safety and liability; agricultural and supply-chain risks; and continued operating losses and cash use.
- FY2021 included $109.5 million of expected credit losses and related charges associated with PharmHouse, which entered creditor-protection proceedings, and a $32.4 million impairment of the PharmHouse equity investment. Fair-value movements in the Acreage liability, CBI warrant liability, convertible notes and other investments materially affected reported earnings.
- The Acreage acquisition remains conditional on a U.S. federal-law triggering event and other conditions. After year-end, Canopy acquired Ace Valley and agreed to acquire Supreme Cannabis, subject to approvals and closing conditions. These were subsequent events, not completed FY2021 acquisitions.
- CBI held approximately 37.1% of outstanding common shares as of May 28, 2021 and could reach approximately 54.3% after full warrant exercise and note conversion, assuming no other share changes. Potential share issuance and CBI’s governance rights may affect dilution and control.
- Disclosed litigation includes a proposed Canadian cannabis-labeling class action seeking $505 million in damages, apparently among multiple defendants; a U.S. securities case was dismissed without prejudice, with an opportunity to replead; and a separate $500 million claim in Ontario in which plaintiffs’ counsel indicated Canopy might be discontinued. Outcomes and any Canopy-specific exposure are not clear from the filing text.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Management also reported disclosure controls and internal control over financial reporting effective at March 31, 2021.
Most important facts for investors to verify
- Confirm the correct period: this is FY2021, ending March 31, 2021; the quarterly figures show March-quarter revenue of $148.4 million and net loss of $616.7 million.
- Review the financial statements and cash-flow notes to assess recurring cash burn, capital spending, and whether reported liquidity can support operations and scheduled obligations.
- Examine the debt agreement’s security, high floating-rate cost, liquidity covenant and refinancing exposure, alongside the $600 million 4.25% convertible notes due July 2023.
- Assess the assumptions behind the large non-cash Level 3 fair-value balances and earnings effects, particularly the Acreage liability and CBI warrant derivative liability.
- Track whether restructuring delivers durable margin improvement, and whether volume growth can offset price compression and underused capacity.
- Check the status and potential dilution from the Acreage arrangement, CBI warrants and notes, and the post-year-end Supreme Cannabis transaction.
- Follow developments in the PharmHouse-related losses and disclosed litigation, including the amount, if any, attributable to Canopy.